10-Q: Cibus Narrows Losses, Boosts Cash Amid Strategic Shift

Cibus, Inc. reported reduced net losses and increased cash reserves for the nine months ended September 30, 2025, driven by cost-cutting and a sharpened focus on its Rice weed management traits.

Summary

• Net loss for the nine months ended September 30, 2025, significantly improved to $100.3 million, compared to $256.9 million for the same period in 2024.
• Revenue decreased by 15% to $2.6 million for the nine months ended September 30, 2025, from $3.1 million in the prior year, primarily due to lower collaboration agreement earnings.
• Research and development (R&D) expenses decreased by 8% to $34.8 million, and selling, general, and administrative (SG&A) expenses decreased by 9% to $21.8 million, both attributed to cost reduction initiatives.
• Goodwill impairment was $21.0 million for the nine months ended September 30, 2025, a substantial decrease from $181.4 million in the prior year.
• Cash and cash equivalents increased to $23.9 million as of September 30, 2025, up from $14.4 million at December 31, 2024.
• Cash used in operating activities decreased by 16% to $37.2 million for the nine months ended September 30, 2025, compared to $44.0 million in the prior year.
• The company completed two follow-on offerings in January and June 2025, raising approximately $21.4 million and $25.0 million in net proceeds, respectively.
• A workforce reduction of approximately 34 full-time employees is expected to be completed by December 31, 2025, as part of a streamlined business focus on Rice weed management traits.
• The company projects its annual net cash usage to reduce to approximately $30.0 million by 2026 due to cost reduction actions.

Sentiment

Score: 4

Explanation: While the company shows strong operational progress, regulatory wins, and a clear strategic focus, its severe liquidity issues, continued significant losses, and explicit 'going concern' warning indicate a high level of financial risk. The positive operational developments are overshadowed by the immediate need for substantial capital.

Positives

• Net loss significantly decreased by 61% to $100.3 million for the nine months ended September 30, 2025, compared to $256.9 million in the prior year.
• Cash and cash equivalents increased to $23.9 million as of September 30, 2025, from $14.4 million at December 31, 2024.
• Cash used in operating activities decreased by 16% to $37.2 million, indicating improved operational efficiency and cost control.
• Goodwill impairment charges were substantially lower at $21.0 million compared to $181.4 million in the prior year.
• Achieved significant regulatory milestones, including California's first authorization for planting gene-edited Rice and multiple 'not regulated' designations from USDA-APHIS for Canola traits.
• Secured material transfer agreements with Semillano (Colombia) and CIAT (Latin America) to advance commercialization of Rice herbicide tolerance traits.
• Entered an agreement with AgVay to develop a strategy for expanding Cibus' presence in India, a major rice market.
• Successfully completed pre-commercial pilot runs and received initial payments for the sustainable ingredients program, validating its commercial potential.
• Positive field trial results for second-generation HT2 edited Canola confirmed acceptable herbicide resistance and similar yield to unedited parent.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $827.0 million as of September 30, 2025.
• Revenue decreased by 15% for the nine months ended September 30, 2025, compared to the prior year, indicating a decline in collaboration agreement earnings.
• Existing cash and cash equivalents are not sufficient to fund operations for 12 months from the filing date, raising substantial doubt about the company's ability to continue as a going concern.
• The company will need to raise additional capital in the near term, which could result in substantial dilution to existing stockholders.
• Accrued a $2.6 million litigation liability in the third quarter of 2025, representing an unplanned repayment of previously awarded insurance proceeds.
• The ATM (at-the-market) facility, which could have provided additional capital, was terminated during the third quarter of 2025.

Risks

• The company needs additional near-term funding to finance its activities and faces challenges in obtaining additional capital on acceptable terms, or at all.
• Changes in expected or existing competition could adversely affect the company's market position and financial performance.
• Challenges to the company's intellectual property protection and unexpected costs associated with defending intellectual property rights pose a risk.
• Increased or unanticipated time and resources may be required for the company's development efforts for its priority opportunities in Rice and biofragrance products and sustainable ingredients.
• Reliance on third parties for development activities and commercialization introduces operational and financial risks.
• Challenges associated with the company's ability to effectively license its productivity traits and sustainable ingredient products could hinder revenue generation.
• There is a risk that farmers may not recognize the value in germplasm containing the company's traits, or that farmers and processors fail to work effectively with such crops.
• Delays or disruptions in the company's platform or trait product development efforts could impact commercialization timelines.
• The inability to identify partners to fund the company's non-Rice productivity trait portfolio could limit its development.
• Challenges in producing high-quality plants and seeds cost-effectively on a large scale could affect profitability.
• Regulatory developments that disfavor or impose significant burdens on gene editing processes or products, including delays and uncertainties in the European Union, could impact market access.
• The company's streamlined business focus may result in operational and strategic challenges, including loss of institutional knowledge, unplanned attrition, and reduced employee morale.
• There is no assurance that management's assumptions regarding demand for end-products containing Cibus' licensed intellectual property are correct, and any failure to realize such demand could have a material adverse effect.

Future Outlook

The company anticipates continued losses for the next several years but expects to reduce its annual net cash usage to approximately $30.0 million by 2026 through ongoing cost reduction initiatives. It plans to finance future cash needs through existing cash, commercialization activities (including upfront and milestone payments, license fees, and royalties), government or third-party funding, and public or private equity or debt financings. Initial commercial launches for Rice herbicide tolerance traits are targeted for Latin America in 2027 and the United States in 2028, with commercial expansion for sustainable ingredients planned for 2026.

Management Comments

• Management believes its Rice herbicide tolerance traits represent potential annual accessible royalties of over $200 million upon full commercialization across target markets.
• The company anticipates that the cost reduction actions announced to date have the potential to reduce its annual net cash usage to approximately $30.0 million by 2026, contributing to improved cash flow and financial stability.
• Management believes its cash and cash equivalents as of September 30, 2025, are not sufficient to fund operations for a period of 12 months or more from the date of this filing, necessitating additional capital raises.
• The company believes ongoing harmonization of regulatory frameworks will open significant new market opportunities for gene editing technologies.
• Management states that 2025 to date has demonstrated clear advancement of the company's strategy and the transformative potential of its RTDS technology platform.

Industry Context

Cibus operates in the agricultural biotechnology sector, leveraging gene-editing technologies to develop plant traits. The industry is experiencing a shift towards gene-edited products, which are increasingly favored over genetically modified organisms (GMOs) due to more favorable regulatory treatment in key markets like the U.S., Canada, Argentina, and Ecuador. The ongoing regulatory advancements in the EU and UK for New Genomic Techniques (NGTs) and Precision Bred Organisms (PBOs) signal a potential opening of large new markets and the establishment of global trade and cultivation guidelines. Cibus' focus on herbicide tolerance in Rice addresses critical productivity challenges in a major global food crop, aligning with broader industry trends towards sustainable and efficient farming solutions.

Comparison to Industry Standards

• Cibus' RTDS-developed trait products are confirmed as non-transgenic by numerous regulatory agencies in the Americas (U.S., Canada, Argentina), distinguishing them from GMO technologies that face regulatory and adoption headwinds, particularly in the European Union.
• The company's achievement of field trial results for stacked gene-edited herbicide tolerance traits in Rice is noted as the first known trial of its kind, positioning Cibus as a leader in this specific application.
• The regulatory determination in Ecuador that Cibus' HT1 and HT3 Rice traits are equivalent to conventionally bred and not subject to strict GMO prohibitions reinforces the company's view of a globally supportive regulatory environment for gene editing, contrasting with historical challenges faced by traditional GMO developers.
• Cibus' participation as a test case for the UK's new review process for Precision Bred Organisms (PBOs) demonstrates its proactive engagement in shaping and adapting to evolving regulatory standards, potentially giving it an advantage over competitors less involved in policy development.

Management Changes

Legal Proceedings

• Accrued $2.6 million for litigation liability in the third quarter of 2025, representing a repayment of insurance coverage proceeds previously awarded, based on an unexpected decision from the Ninth Circuit Court of Appeals. This repayment is expected in the fourth quarter of 2025.

Related Party Transactions

• Royalty Liability related parties: $225.517 million as of September 30, 2025, representing future royalty payments to certain investors, including directors and affiliated entities.
• Mr. Riggs, a director, was involved in the January 2025 Follow-On Offering, receiving 2025 Pre-Funded Warrants and having his 2024 Common Warrants amended.
• Mr. Riggs also received 5,714,286 shares of Class A Common Stock in the June 2025 SEC-Registered Public Offering.

Stakeholder Impact

• Shareholders face potential significant dilution from future equity capital raises due to the company's ongoing need for funding.
• Employees are impacted by a workforce reduction of approximately 34 full-time employees, which could affect morale and institutional knowledge.
• Customers and partners benefit from new material transfer agreements and the delivery of Rice lines, indicating progress in product commercialization.
• Creditors (Royalty Holders) are owed a significant royalty liability, which continues to accrue interest.
• The company's strategic focus on Rice and sustainable ingredients aims to create long-term value for shareholders and address global agricultural challenges.

Next Steps

• Complete the reduction in workforce of approximately 34 full-time employees by December 31, 2025.
• Implement the streamlined business focus and related cost reduction actions over the remainder of 2025.
• Continue to advance bio-based fermentation biofragrance products and crop-based sustainable ingredients programs.
• Pursue partner-funded projects for non-Rice productivity trait portfolio opportunistically.
• Target initial commercial launches of Rice herbicide tolerance traits in Latin America beginning in 2027 and expanding to the United States in 2028.
• Plan for targeted commercial expansion of sustainable ingredients program in 2026.
• Develop a comprehensive strategy with AgVay to expand Cibus' presence in India for rice traits.
• Raise additional capital to support business plans and ensure continuation as a going concern.

Key Dates

Recommendation

Despite significant operational progress, regulatory wins, and a clear strategic focus, the company's explicit 'going concern' warning, substantial accumulated deficit, and insufficient cash to fund operations for the next 12 months present an immediate and severe financial risk. While cost-cutting measures and recent capital raises provide some temporary relief, the ongoing need for substantial additional capital, with the potential for significant shareholder dilution, makes the stock highly speculative and vulnerable. A seasoned investor would likely view the fundamental financial instability as outweighing the promising long-term technological developments, leading to a 'sell' recommendation to mitigate risk until a clear path to sustainable profitability and adequate liquidity is established.

Keywords

Gene Editing, Agricultural Biotechnology, Plant Traits, Rice Weed Management, Sustainable Ingredients, RTDS, Canola, Herbicide Tolerance, SEC Filing, 10-Q, Financial Results, Biotech, Crop Science, Regulatory Approval